2004
DOI: 10.1016/j.amjmed.2003.10.037
|View full text |Cite
|
Sign up to set email alerts
|

Health care lobbying in the United States

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
15
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 42 publications
(15 citation statements)
references
References 13 publications
0
15
0
Order By: Relevance
“…Pharmaceutical Lobby. Pharmaceutical lobbying is another controversial issue that affects many parts of the world [22,23,24,25]. Among its many aspects, we focus on the marketing practices of large pharmaceutical companies which manipulate the opinions of doctors, health care providers and law-makers by providing biased information and through other tactics [26,27].…”
Section: Search Engine Biasmentioning
confidence: 99%
“…Pharmaceutical Lobby. Pharmaceutical lobbying is another controversial issue that affects many parts of the world [22,23,24,25]. Among its many aspects, we focus on the marketing practices of large pharmaceutical companies which manipulate the opinions of doctors, health care providers and law-makers by providing biased information and through other tactics [26,27].…”
Section: Search Engine Biasmentioning
confidence: 99%
“…Conflict over the distributional effects of policies that affect health and health care, for example, can be expensive. 3,4 Efforts to address obesity through structural intervention are likely to be similarly expensive. 5 Thus, although the direct costs of policy change may amount to very little (as Katz correctly notes), the social costs can be quite substantial.…”
Section: Indirect Costs Of Structural Interventionsmentioning
confidence: 99%
“…3 In the United States, women of lower socioeconomic status or low educational level, ethnic minorities, and immigrants are significantly more likely to both develop and die of cervical cancer. 4 More than differences in individual risk, these disparities arise from the systematic inability of underserved groups to access health care services, such as regular screening and prompt treatment of premalignant cervical lesions. 5 Despite its limitations, the HPV vaccine has the potential to reduce the existing disparity in cervical cancerrelated morbidity and mortality.…”
mentioning
confidence: 99%
“…Pharmaceutical lobbying is another controversial issue that affects many parts of the world [22,23,24,25]. Among its many aspects, we focus on the marketing practices of large pharmaceutical companies which manipulate the opinions of doctors, health care providers and law-makers by providing biased information and through other tactics [26,27].…”
Section: Applicationsmentioning
confidence: 99%